CD163 and colorectal cancer: Interestingly, in colorectal cancers (CRCs), CD163-positive M2-like macrophages exhibit anti-tumor activity in tumors with low levels of the anti-phagocytotic marker CD47 and positively correlate with the expression of CD68, which predicts increases in long-term survival [49].